Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

There are problems within the health system that mean full patient access to training on how to use the insulin pumps will ...

Robert Ford’s comments come as new CGMs and insulin pumps continue to roll out in the diabetes tech space, including over-the-counter glucose sensors.

Abbott’s earnings for the third quarter (Q3) of 2024 saw global sales reach $10.6 billion, a strong performance driven by the ...

Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items. Abbott maintains its full-year 2024 organic sales growth guidance range ...

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...

Pharmac's decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live ...

To meet international guidelines, New Zealand needs to double the workforce that supports people with diabetes. Unless that ...

DexCom, Inc. (NASDAQ:DXCM) has also consistently beat EPS estimates in the last 4 quarters. The stock has received an average ...

By personalizing insulin dosing based on individual patient data, the system outperforms traditional insulin pumps in terms ...